FDA Approves Subcutaneous Risankizumab for Adults with Moderately to Severely Active Crohn's Disease

The U.S. Food and Drug Administration (FDA) has approved a subcutaneous induction regimen of risankizumab (Skyrizi, AbbVie) for adults suffering from moderately to severely active Crohn's disease. This regulatory action provides a new treatment option for patients with this inflammatory bowel disease.